Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) traded down 4.1% during trading on Friday . The company traded as low as $52.11 and last traded at $53.94. 73,998 shares changed hands during trading, a decline of 85% from the average session volume of 505,200 shares. The stock had previously closed at $56.23.
Apogee Therapeutics Price Performance
The business's 50 day simple moving average is $51.68 and its 200 day simple moving average is $48.77. The company has a market capitalization of $3.13 billion, a PE ratio of -10.38 and a beta of 2.75.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). As a group, analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.
Insider Buying and Selling at Apogee Therapeutics
In other Apogee Therapeutics news, insider Carl Dambkowski sold 7,335 shares of Apogee Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $40.67, for a total transaction of $298,314.45. Following the completion of the sale, the insider now directly owns 287,458 shares in the company, valued at $11,690,916.86. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Apogee Therapeutics news, insider Carl Dambkowski sold 7,335 shares of Apogee Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $40.67, for a total transaction of $298,314.45. Following the completion of the sale, the insider now directly owns 287,458 shares in the company, valued at $11,690,916.86. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the sale, the chief executive officer now owns 1,434,487 shares of the company's stock, valued at approximately $58,268,861.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 146,665 shares of company stock worth $7,058,635 over the last three months. Insiders own 36.10% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in APGE. EntryPoint Capital LLC grew its holdings in shares of Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after purchasing an additional 617 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Apogee Therapeutics in the second quarter valued at approximately $143,000. Kennedy Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the first quarter valued at approximately $212,000. Arizona State Retirement System grew its holdings in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock valued at $236,000 after purchasing an additional 258 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock worth $253,000 after acquiring an additional 1,340 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Further Reading
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
